Kameyama et al. studied parental and gemcitabine-resistant T24 urothelial carcinoma cell lines and found that the gemcitabine-resistant cells overexpressed AR at the mRNA and protein levels and had reduced proliferation with enzalutamide treatment [27]. Here, AR is linked to urothelial carcinoma.